Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A(2A)/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia

Brain Research Reviews

Volumn 26, Issue 2-3, 1998, Pages 258-273

  Fuxe, Kjell ^a   Ferré, Sergi ^a   Zoli, Michele ^b   Agnati, Luigi F ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adenosine receptors; Basal ganglia; Dopamine receptors; Membrane; Receptor receptor interactions

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BASAL GANGLION; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; BRAIN; DIMERIZATION; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, NEUROLOGICAL; NEURONS; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D1; RECEPTORS, PURINERGIC P1; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 0032078541     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(97)00049-0     Document Type: Conference Paper

References (75)

1. Agnati L., Fuxe K., Zini I., Lenzi P., Hökfelt T. Aspects on receptor regulation and isoreceptor identification. Med. Biol. 58:1980;182-187.
2. Agnati L., Fuxe K., Zoli M., Rondanini C., Ögren S.-O. New vistas on synaptic plasticity: mosaic hypothesis on the engram. Med. Biol. 60:1982;183-190.
3. 3H -N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro Biosci. Reports. 3:1983;1101-1105.
4. Agnati L., Ferré S., Cortelli P., Fuxe K. A brief appraisal on some aspects of the receptor-receptor interaction. Neurochem. Int. 27:1995;139-146.
5. 3H -N-propylnorapomorphine binding sites Acta. Physiol. Scand. 119:1983;459-461.
6. L.F. Agnati, K. Fuxe, F. Benfenati, N. Battistini, I. Zini, M. Camurri, T. Hökfelt, Postsynaptic effects of neuropeptide comodulators at central monoamine synapses, in: E. Usdin, A. Carlsson, A. Dahlström, J. Engel (Eds.), Neurology and Neurobiology, Alan R. Liss, New York, 1984, pp. 191-198.
7. Agnati L.F., Benfenati F., Solfrini V., Biagini G., Fuxe K., Guidolin D., Carani C., Zini I. Intramembrane receptor-receptor interactions: integration of signal transduction pathways in the nervous system. Neurochem. Int. 22:1993;213-222.
8. Collis M.G., Hourani S.M.O. Adenosine receptor subtypes. Trends in Pharmacol. Sci. 14:1993;360.
9. Conn P.M., Rogers D.C., Stewart J.M., Niedel J., Sheffield T. Conversion of a gonadotropin-releasing hormone antagonist to an agonist. Nature. 296:1982;653-655.
10. 2 receptors in stably cotransfected fibroblast cells. Eur. J. Pharmacol. 316:1996;325-331.
11. 2A receptor in the rat striatum. J. Neurochem. 69:1997;315-321.
12. 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA. 88:1991;7238-7241.
13. 2 mediated behaviour in short-term reserpinized mice. Eur. J. Pharmacol. 192:1991;30-35.
14. 2 receptors in the neostriatum. Brain Res. 594:1992;124-130.
15. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B. Adenosine-dopamine interactions in the brain. Neuroscience. 51:1992;501-512.
16. Ferré S., O'Connor W., Fuxe K., Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13:1993;5402-5406.
17. 2 receptors in rat neostriatal membranes. Eur. J. Pharmacol. - Mol. Pharmacol Section. 244:1993;311-315.
18. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience. 63:1994;765-773.
19. 1 receptors. NeuroReport. 6:1994;73-76.
20. 2 receptors in the neostriatum. Psychopharmacology. 116:1994;279-284.
21. 1 receptor-mediated mechanisms. Eur. J. Neurosci. 8:1996;1545-1553.
22. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor ineractions as an integrative mechanism in the basal ganglia. Trends in Neurosci. 20:1997;482-487.
23. 2 receptors in the rat striatum, J. Neurosci. (1997) submitted.
24. 1 receptors in stably cotransfected fibroblast cells, J. Biol. Chem. (1997) in press.
25. Fredholm B.B. Purinoceptors in the nervous system. Pharmacol. Toxicol. 76:1995;228-239.
26. 3H]-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta. Physiol. Scand. 113:1981;567-569.
27. Fuxe K., Agnati L.F., Benfenati F., Celani M.F., Zini I., Zoli M., Mutt V. Evidence for the existence of receptor-receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuroleptics. J. Neural Transm. 18:1983;165-179.
28. K. Fuxe, L.F. Agnati, K. Andersson, M. Martire, S.O. Ögren, L. Giardino, N. Battistini, R. Grimaldi, C. Farabegoli, A. Härfstrand, G. Toffano, Receptor-receptor interactions in the central nervous system. Evidence for the existence of heterostatic synaptic mechanisms, in: E.S. Vizi, K. Magyar (Eds.), Regulation of Transmitter Function: Basic and Clinical Aspects. Developments in Neuroscience Series, Vol. 17., Akadémiai Kiadó, Budapest, 1984, pp. 129-140.
29. Fuxe K., Agnati L. Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med. Res. Rev. 5:1985;441-482.
30. K. Fuxe, L.F. Agnati, Receptor-receptor interactions. A new intramembrane integrative mechanism, Macmillan Press, London, 1987.
31. K. Fuxe, L.F. Agnati, G. von Euler, F. Benfenati, M. Zoli, A. Härfstrand, B. Fredholm, Receptor-receptor interactions and development of psychoactive drugs, in: E. Costa (Ed.), Neurochemical pharmacology, Raven Press, New York, 1989, pp. 211-227.
32. 2 transmission lines in the central nervous system, in: N. Osborne (Ed.), Current Aspects in the Neurosciences, Vol. 1, MacMillan Press, Basingstoke, 1990, pp. 203-243.
33. 2 receptors via intramembrane receptor-receptor interactions. Relevance for Parkinson's disease and schizophrenia. Neurochem. Int. 20:1992;215-224.
34. Fuxe K., O'Connor W.T., Antonelli T., Osborne P.G., Tanganelli S., Agnati L.F., Ungerstedt U. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc. Natl. Acad. Sci. USA. 89:1992;5591-5595.
35. 2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. N.Y. Acad. Sci. 668:1992;186-204.
36. 2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug. Dev. Res. 28:1993;374-380.
37. Fuxe K., Li X.M., Bjelke B., Hedlund P.B., Biagini G., Agnati L.F. Possible mechanisms for the powerful actions of neuropeptides. Ann. N.Y. Acad. Sci. 739:1994;42-59.
38. K. Fuxe, X-M. Li, S. Tanganelli, P. Hedlund, W.T. O'Connor, L. Ferraro, U. Ungerstedt, L.F. Agnati, Receptor-receptor interactions and their relevance for receptor diversity, in: L. Abood, A. Lajtha (Eds.), Diversity of interacting receptors, 1995, pp. 365-376.
39. 2 receptor interactions in the basal ganglia: analysis from the network to the molecular level, in: L. Belardinelli, A. Pelleg (Eds.), Adenosine and adenine nucleotides: From molecular biology to integrative physiology, Kluwer, Boston, MA, 1995, pp. 499-507.
40. K. Fuxe, X-M. Li, P. Hedlund, F. Benfenati, L.F. Agnati, S. Ferré, Integrative aspects of brain function: Receptor-receptor interactions in dopamine transmission of the basal ganglia, in: T.W. Stones (Ed.), CNS Neurotransmitters and Neuromodulators. Dopamine, CRC Press, Boca Raton, Florida, 1996, pp. 89-106.
41. K. Fuxe, T. Hökfelt, L. Olson, D. Ottoson, A. Dahlström, A. Björklund, Molecular Mechanisms of Neuronal Communication. A Tribute to Nils-Åke Hillarp, Wenner-Gren Int. Series, Vol. 68, Pergamon, Oxford, 1996.
42. Gilman A.G. G-proteins: Transducers of receptor-generated signals. Ann. Rev. Biochem. 56:1987;615-627.
43. Gingricg J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. Ann. Rev. Neurosci. 16:1993;299-321.
44. D.O. Hebb, The organization of behavior, Wiley, New York, 1949.
45. Hebert T.E., Moffett S., Morello J.-P., Loisel T.P., Bichet D.G., Barret C., Bouvier M. A peptide derived from a β2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271:1996;16384-16392.
46. Hollenberg M.D. Structure-activity relationships for transmembrane signaling: the receptor's turn. FASEB J. 5:1991;178-186.
47. 2 receptor stimulation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J. Pharmacol. Exp. Ther. 267:1993;801-808.
48. 2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation. Eur. J. Pharmacol. 287:1995;115-120.
49. R.J. Lasek, Studying the intrinsic determinants of neural form and function, in: R.J. Lasek, M.M. Black (Eds.), Intrinsic Determinants of Neural Form and Function, Liss, New York, 1988, pp. 463-486.
50. 2A receptors, Neurosci. Lett. (1997) submitted.
51. 2 receptors in rat forebrain sections. Eur. J. Neuroscience. 7:1995;962-971.
52. 2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Commun. 173:1990;1169-1178.
53. Maggio R., Barbier P., Fornai F., Corsini G.U. Functional role of the third cytoplasmic loop in muscarinic receptor dimerization. J. Biol. Chem. 271:1996;31055-31060.
54. Maggio R., Vogel Z., Weiss J. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular 'cross-talk' between G-protein-linked receptors. Proc. Natl. Acad. Sci. USA. 90:1993;3103-3107.
55. 2 receptor interaction in globus pallidus. Synapse. 22:1996;132-138.
56. 2 receptor stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 67:1995;49-55.
57. 2 receptor dimers and receptor-blocking peptides. Biochem. Biophys. Res. Commun. 227:1996;200-204.
58. 2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J. Neurochem. 65:1995;2057-2064.
59. 1 agonists in dopamine-denervated rats. Eur. J. Neurosci. 8:1996;1176-1181.
60. 1 receptor activation in rabbits. Eur. J. Pharmacol. 305:1996;123-126.
61. 1 receptor stimulation in rodents. Neurosci. Lett. 218:1996;209-213.
62. 2A agonists: A potential new type of atypical antipsychotic. Neuropsychopharmacology. 17:1997;82-91.
63. Romano C., Yang W.L., O'Malley K.L. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem. 271:1996;28612-28616.
64. Rothman R.B., Long J.B., Bykov V., Jacobsen A.E., Rice K.C., Holaday J.W. Beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J. Pharmacol. Exp. Ther. 247:1988;405-416.
65. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
66. Schlessinger J. Signal transduction by allosteric receptor oligomerization. Trends Biochem. Sci. 13:1988;443-447.
67. 2a receptor cDNA. Biochem. Pharmacol. 48:1994;2043-2047.
68. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
69. 2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology. 111:1993;383-388.
70. Venter J.C., Fraser C.M. Beta-adrenergic receptor isolation and characterization with immobilized drugs and monoclonal antibodies. Fed. Proc. 42:1983;273-278.
71. 2 receptors in rat striatal membranes. Acta Phys. Scand. 131:1987;525-526.
72. 2 (long-form) receptor co-transfected mouse fibroblast cell lines: Studies on intracellular calcium levels. Neuroscience. 68:1995;729-736.
73. Zoli M., Agnati L.F., Hedlund P., Li X., Ferré S., Fuxe K. Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol. Neurobiol. 7:1993;293-334.
74. Zoli M., Guidolin D., Fuxe K., Agnati L.F. The receptor mosaic hypothesis of the engram: Possible relevance of Boolean network modeling. Int. J. Neural Systems. 7:1996;363-368.
75. S.O. Ögren, The behavioural pharmacology of typical and a typical antipsychotic drugs, in: J.G. Csernansky (Ed.), Handbook of Experimental Pharmacology, Springer, Berlin, 1996, pp. 225-266.